← Back to Screener
Exicure, Inc. Common Stock (XCUR)
Price$3.86
Favorite Metrics
Price vs S&P 500 (26W)-29.61%
Price vs S&P 500 (4W)-16.51%
Market Capitalization$24.14M
All Metrics
Book Value / Share (Quarterly)$0.62
P/TBV (Annual)242.39x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.34
Price vs S&P 500 (YTD)-29.64%
Net Profit Margin (TTM)-165.80%
EPS (TTM)$-0.77
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-0.77
Revenue Growth (5Y)-17.40%
EPS (Annual)$-0.79
ROI (Annual)-125.98%
Net Profit Margin (5Y Avg)-4559.15%
Cash / Share (Quarterly)$0.59
ROA (Last FY)-35.23%
EBITD / Share (TTM)$-0.87
ROE (5Y Avg)-283.38%
Operating Margin (TTM)-167.20%
Cash Flow / Share (Annual)$-1.34
P/B Ratio6.15x
P/B Ratio (Quarterly)8.77x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)40.80x
Net Interest Coverage (TTM)-1937.60x
ROA (TTM)-28.79%
EV / EBITDA (TTM)5.12x
EPS Incl Extra (Annual)$-0.79
Current Ratio (Annual)1.19x
Quick Ratio (Quarterly)1.04x
3-Month Avg Trading Volume0.48M
52-Week Price Return-66.27%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.02
P/S Ratio (Annual)48.29x
Asset Turnover (Annual)0.03x
52-Week High$12.65
Operating Margin (5Y Avg)-4551.11%
EPS Excl Extra (Annual)$-0.79
CapEx CAGR (5Y)-80.06%
Tangible BV CAGR (5Y)-5.67%
26-Week Price Return-25.63%
Quick Ratio (Annual)1.04x
13-Week Price Return-32.25%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.19x
Enterprise Value$20.398
Revenue / Share Growth (5Y)-18.42%
Asset Turnover (TTM)0.05x
Book Value / Share Growth (5Y)-50.73%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1938.60%
Cash / Share (Annual)$0.59
3-Month Return Std Dev75.79%
Net Income / Employee (TTM)$-1
ROE (Last FY)-125.98%
Net Interest Coverage (Annual)-391.44x
EPS Basic Excl Extra (Annual)$-0.79
Receivables Turnover (TTM)-49.20x
EV / Free Cash Flow (TTM)0.48x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.77
ROI (TTM)-63.62%
P/S Ratio (TTM)48.29x
Pretax Margin (5Y Avg)-4558.68%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.02
Price vs S&P 500 (52W)-96.10%
Year-to-Date Return-27.00%
5-Day Price Return-3.50%
EPS Normalized (Annual)$-0.79
ROA (5Y Avg)-71.11%
Net Profit Margin (Annual)-1940.20%
Month-to-Date Return-7.00%
Cash Flow / Share (TTM)$0.67
EBITD / Share (Annual)$-0.87
Operating Margin (Annual)-2365.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-239.74%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.77
P/TBV (Quarterly)242.39x
P/B Ratio (Annual)8.77x
Pretax Margin (TTM)-165.80%
Book Value / Share (Annual)$0.62
Price vs S&P 500 (13W)-32.94%
Beta4.05x
P/FCF (Annual)100.60x
Revenue / Share (TTM)$0.00
ROE (TTM)-63.62%
52-Week Low$3.10
Analyst Recommendations
Oct 2022
Nov 2022
Dec 2022
Jan 2023
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
XCURExicure, Inc. Common Stock | 48.29x | — | — | — | $3.86 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Exicure Inc is an early-stage biotechnology company developing nucleic acid therapeutics targeting validated disease pathways. The company specializes in RNA-based therapeutic approaches to address unmet clinical needs.